Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis

Next Previous
Trial Profile

A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms 16Y-LTF; 20Y-LTF; 21Y-LTF
  • Sponsors Berlex Laboratories

Most Recent Events

  • 30 Jun 2010 Added trial investigator, actual no. of pts and updated trial comment.
  • 08 Jun 2010 Results from the 16-year follow-up to the pivotal Betaferon trial published in Neurology, according to a Bayer HealthCare media release.
  • 29 Apr 2009 New data analyses presented at 61st Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top